Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.
Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.